Manufacturing mesenchymal stromal cells for phase I clinical trials

作者:Hanley, Patrick J.*; Mei, Zhuyong; Cabreira-Hansen, Maria da Graca; Klis, Mariola; Li, Wei; Zhao, Yali; Durett, April G.; Zheng, Xingwu; Wang, Yongping; Gee, Adrian P.; Horwitz, Edwin M.
来源:Cytotherapy, 2013, 15(4): 416-422.
DOI:10.1016/j.jcyt.2012.09.007

摘要

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus-host disease and Crohn's disease as well as regenerative applications such as stroke and congestive heart failure. We report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices facility.

  • 出版日期2013-4